Article thumbnail

Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI)

By Eric Leith, Tom Bowen, Joe Butchey, David Fischer, Harold Kim, Bill Moote, Peter Small, Don Stark and Susan Waserman
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2876183
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003;131:111–8. 60 Allergy, Asthma,
  2. A double-blind, placebo-controlled birch allergen vaccination study: inhibition of CD23-mediated serum-immunoglobulin E–facilitated allergen presentation.
  3. (1994). A double-blind, placebo-controlled trial by sublingual route of immunotherapy with a standardized grass pollen extract. Allergy
  4. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Specific allergen immunotherapy for asthma.
  5. (1994). AAAAI position statement 25. Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergen extracts.
  6. (1978). Acontrolled trial of immunotherapy in insect hypersensitivity.
  7. Advances in upper airway diseases and allergen immunotherapy.
  8. (2004). Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
  9. Adverse effects of allergen immunotherapy: assessment and treatment. In:
  10. (1993). Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
  11. (2003). Allergen immunotherapy for asthma. Cochrane Database Syst Rev
  12. (2003). Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol
  13. Allergen immunotherapy: practice parameter,
  14. (1998). Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.
  15. (2004). Allergen immunotherapy: therapeutic vaccines for asthma. In:
  16. Allergens and allergen immunotherapy—practical clinical applications.
  17. Allergic rhinitis and its impact on asthma.
  18. (2001). Allergic rhinitis/asthma interrelationships. Clin Rev Allergy Immunol
  19. American Academy of Allergy Asthma and Immunology/American College of Physicians.
  20. (2004). Anti-IgE therapy. In:
  21. (1999). Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.
  22. (1999). Can the natural course of allergy and asthma be changed by allergen vaccination? Allergy
  23. (1995). Canadian Society of Allergy and Clinical Immunology. Guidelines for the use of allergen immunotherapy.
  24. (2004). Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol
  25. (2000). Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebocontrolled study. Allergy
  26. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebocontrolled, double-blind, double-dummy study.
  27. Clinical laboratory assessment of IgE-dependent hypersensitivity.
  28. (2004). Cockroach and other inhalant insect allergens.
  29. (1986). Committee on safety of medicine. CSM update. Desensitization vaccines.
  30. Comparison of test devices for skin prick testing.
  31. Consensus statement on the treatment of allergic rhinitis.
  32. (1996). Deaths associated with skin testing and immunotherapy (abstract).
  33. (1977). Diagnostic tests in the skin and serum of workers sensitized to Bacillus subtilis enzymes. Clin Allergy
  34. (2002). Education and Prevention Program. Expert Panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol
  35. (1997). Education and Prevention Program. Practical guide for the diagnosis and management of asthma.
  36. (1994). Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinitis. Allergy
  37. (1997). Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol
  38. (1999). Efficacy of immunotherapy. In:
  39. (2001). Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica: a double-blind study. Allergol Immunopathol
  40. (1993). Emerging concepts in mold allergy: what is the role of immunotherapy.
  41. (1999). Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy.
  42. (1987). Fatalities from immunotherapy (IT) and skin testing (ST).
  43. (1998). Future directions for allergen immunotherapy.
  44. (2003). Global initiative for asthma. Global strategy for asthma management and prevention.
  45. (1999). Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy
  46. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
  47. (1993). Guidelines on the management of asthma. Thorax
  48. (1998). Immunologic changes associated with allergen immunotherapy.
  49. (1996). Immunotherapy as preventive allergy treatment (PAT) (abstract).
  50. Immunotherapy for inhalant allergy In:
  51. (1999). Immunotherapy in asthma: an updated systemic review. Allergy
  52. Immunotherapy in children.
  53. Immunotherapy of allergic diseases.
  54. (1997). Immunotherapy with a standardized Dermatophagoides extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.
  55. (1991). Immunotherapy with cat and dog dander extracts.
  56. (1984). Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol 1992;90:210–5.
  57. (2003). In vivo methods for study of allergy.
  58. (1999). Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.
  59. Insect sting allergy and venom immunotherapy: a model and a mystery.
  60. (2002). Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol
  61. (2003). Laboratory tests for allergic and immunodeficiency diseases.
  62. (1998). Local immunotherapy. Allergy
  63. (2003). Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy
  64. Mechanisms of immunotherapy.
  65. Medical knowledge self-assessment program
  66. New targets for allergic rhinitis—a disease of civilization.
  67. (2001). New trends in immunotherapy to prevent atopic disease. Trends Pharmacol Sci
  68. (2004). Non-injection routes for immunotherapy for allergic diseases.
  69. Noninjection routes for immunotherapy.
  70. (2004). Novel approaches to immunotherapy for food allergy.
  71. (1997). Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study.
  72. Patterns of pollen cross-allergenicity.
  73. (1990). placebo-controlled rush immunotherapy with a standardized Alternaria extract.
  74. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study).
  75. (1996). Practice parameters for allergen immunotherapy.
  76. (2004). Preparing and mixing allergen vaccines.
  77. (2000). Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebocontrolled, randomized trial. Allergy
  78. (2001). Prevention of anaphylaxis in the office setting.
  79. Prophylactic inoculation against hay fever.
  80. Quantitative assessment of the adherence to sublingual immunotherapy.
  81. (1998). Risk and safety of immunotherapy. Allergy
  82. Safety and clinical efficacy of rush sublingual Juniperus ashei immunotherapy.
  83. (1995). Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double-blind study. Allergol Immunopathol (Madr)
  84. (2000). Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol
  85. (1993). Serum-IgE-facilitated allergen presentation in atopic disease.
  86. Status of immunotherapy: current and future (editorial).
  87. Stinging insect hypersensitivity: a practice parameter update.
  88. (1999). Stinging insect hypersensitivity: a practice parameter.
  89. Sublingual immunotherapy for allergic rhinitis: systemic review and meta-analysis.
  90. (1999). Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy
  91. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms.
  92. Sublingual immunotherapy.
  93. (1999). Summary of recommendations from the Canadian asthma consensus report.
  94. (1995). Summary statements of practice parameters for allergy diagnostic tests. Ann Allergy Asthma Immunol
  95. (1993). Survey of fatalities from skin testing and immunotherapy 1985-1989.
  96. Survey of patients after discontinuing of venom immunotherapy.
  97. The antiinflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
  98. (1994). The appropriate use of skin testing and allergen immunotherapy in young children.
  99. (2004). the Canadian Rhinitis Working Group. Rhinitis: a practical and comprehensive approach to assessment and therapy.
  100. The consideration of immunotherapy in the treatment of allergic asthma.
  101. (2005). The diagnosis and management of anaphylaxis: an updated practice parameter.
  102. The effect of specific immunotherapy on T-cell receptor repertoire in patients with allergy to house-dust mite.
  103. (1995). The high affinity IgE receptor (Fc RI) mediates IgE-dependent allergen presentation.
  104. (2003). The immune system. In:
  105. (2002). The reproducibility of the allergy skin test scoring and interpretation by board certified/board eligible allergists. Ann Allergy Asthma Immunol
  106. (1990). Twelve-year survey of fatal reactions to allergen injections and skin testing:
  107. (2004). Unproven and controversial forms of immunotherapy.
  108. (1998). WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy